<SEC-DOCUMENT>0001213900-25-115615.txt : 20251126
<SEC-HEADER>0001213900-25-115615.hdr.sgml : 20251126
<ACCEPTANCE-DATETIME>20251126172529
ACCESSION NUMBER:		0001213900-25-115615
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251126
DATE AS OF CHANGE:		20251126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bluejay Diagnostics, Inc.
		CENTRAL INDEX KEY:			0001704287
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				473552922
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291042
		FILM NUMBER:		251531556

	BUSINESS ADDRESS:	
		STREET 1:		360 MASSACHUSETTS AVENUE, SUITE 203
		CITY:			ACTON
		STATE:			MA
		ZIP:			01720
		BUSINESS PHONE:		(978) 631-0152

	MAIL ADDRESS:	
		STREET 1:		360 MASSACHUSETTS AVENUE, SUITE 203
		CITY:			ACTON
		STATE:			MA
		ZIP:			01720
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea0267461-424b3_bluejay.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No. 333-291042</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BLUEJAY DIAGNOSTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>6,930,000 Shares of Common Stock </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale, from time
to time, by the selling stockholders identified in this prospectus under the caption &ldquo;Selling Stockholders,&rdquo; or the Selling
Stockholders, of up to 6,930,000 shares of our common stock, par value $0.0001 per share, or the Shares, which are comprised of (i) 175,000
shares of common stock held by one of the Selling Stockholders (the &ldquo;PIPE Shares&rdquo;), (ii) 2,075,000 shares of common stock
issuable to certain of the Selling Stockholders upon the exercise of pre-funded warrants (&ldquo;Pre-Funded Warrants&rdquo;), (iii) 4,500,000
shares of common stock issuable to certain of the Selling Stockholders upon the exercise of series F warrants (&ldquo;Series F Warrants&rdquo;),
and (iv) 180,000 shares of common stock issuable to certain of the Selling Stockholders upon the exercise of placement agent warrants
(&ldquo;Placement Agent Warrants&rdquo; and, together with the Pre-Funded Warrants and the Series F Warrants, the &ldquo;Warrants&rdquo;),
which PIPE Shares and Warrants were issued to the Selling Stockholders in October 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not selling any shares of common stock
under this prospectus and will not receive any proceeds from the sale of shares of common stock by the Selling Stockholders hereunder.
We will, however, receive the net proceeds of any Warrants exercised for cash. The Selling Stockholders will bear all commissions and
discounts, if any, attributable to the sale of the Shares. We will bear all costs, expenses, and fees in connection with the registration
of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may sell the shares of
our common stock offered by this prospectus from time to time on terms to be determined at the time of sale through ordinary brokerage
transactions or through any other means described in this prospectus under the caption &ldquo;Plan of Distribution.&rdquo; The shares
of common stock may be sold at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price
or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market under the symbol &ldquo;BJDX.&rdquo; On November 25, 2025, the closing price of our common stock was $1.38 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock involves a high
degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 10 of this prospectus and under similar headings
in the documents incorporated by reference into this prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is November 26,
2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS<SUP></SUP> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 90%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt">ii</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">The Offering</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">10</TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">12</TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Selling Stockholders</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">13</TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Incorporation By Reference</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale by the Selling
Stockholders identified in this prospectus under the caption &ldquo;Selling Stockholders,&rdquo; from time to time, of up to 6,930,000
shares of our common stock, par value $0.0001 per share. We are not selling any shares of our common stock under this prospectus, and
we will not receive any proceeds from the sale of the Shares offered by the Selling Stockholders hereunder. We will, however, receive
the net proceeds of any Warrants exercised for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
on Form S-3 that we have filed with the Securities and Exchange Commission, or the SEC. Under this registration statement, the Selling
Stockholders may sell from time to time in one or more offerings the common stock described in this prospectus. This prospectus omits
some of the information contained in the registration statement, and reference is made to the full registration statement for further
information with regard to us and the securities being offered by the Selling Stockholders. Any statement contained in the prospectus
concerning the provisions of any document filed as an exhibit to the registration statement or otherwise with the SEC is not necessarily
complete, and in each instance, reference is made to the document filed. You should review the complete document to evaluate such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should carefully read this prospectus, any
documents that we incorporate by reference in this prospectus and the information below under the captions &ldquo;Where You Can Find More
Information&rdquo; and &ldquo;Incorporation of Documents By Reference&rdquo; before making an investment decision. You should rely only
on the information contained or incorporated by reference in this prospectus, or documents to which we otherwise refer you. In addition,
this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to
the actual documents for complete information. We have not authorized any person to provide you with different information. If anyone
provides you with additional, different, or inconsistent information, you should not rely on it. This prospectus is not an offer to sell
these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus includes important information
about us, the securities being offered and other information you should know before investing in our securities. You should not assume
that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this
prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important
for you to read and consider all information contained in this prospectus in making your investment decision. All of the summaries in
this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been
filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part,
and you may obtain copies of those documents as described below under the heading &ldquo;Where You Can Find Additional Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not authorized anyone to provide any information
or to make any representations other than those contained or incorporated by reference in this prospectus or in any free writing prospectuses
prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. The information contained in this prospectus or incorporated by reference
in this prospectus or contained in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery
or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For investors outside the United States: We have
not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for
that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus
must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus
outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This prospectus is an offer to sell only the
securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underwriter
is not, making an offer to sell these securities in any state or jurisdiction where the offer or sale is not permitted. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry and Market Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the documents incorporated
by reference contain estimates, projections and other information concerning our industry, our business, the science of our products and
the markets for our products, including data regarding the incidence of certain medical conditions and the scientific basis of our products.
We obtained the industry, science, market and similar data set forth in this prospectus from our internal estimates and research and from
academic and industry research, publications, surveys, and studies conducted by third parties. While we believe that these industry publications
and third-party research, surveys and studies are reliable, we have not independently verified such data and we do not make any representation
as to the accuracy of the information. The content of the above sources, except to the extent specifically set forth in this prospectus,
does not constitute a portion of this prospectus and is not incorporated herein. Information that is based on estimates, forecasts, projections,
market research, scientific research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances
may differ materially from events and circumstances that are assumed in this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note Regarding Trademarks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the context otherwise requires, references
in this prospectus to &ldquo;Bluejay,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer
to Bluejay Diagnostics, Inc. Our logo and all product names are our common law trademarks. Solely for convenience, trademarks and tradenames
referred to in this prospectus may appear without the &reg; or &trade; symbols, but such references are not intended to indicate in any
way that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its
rights, to these trademarks and tradenames. We do not intend the use or display of other companies&rsquo; trademarks and trade names to
imply a relationship with, or endorsement or sponsorship of us by, any other companies, products or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 15, 2024, we filed a certificate of
amendment to our restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse
stock split of our issued and outstanding shares of common stock, par value $0.0001 per share (the &ldquo;November 2024 Reverse Stock
Split&rdquo;), which became effective on November 18, 2024. All historical share and per share amounts reflected throughout this prospectus
have been adjusted to reflect the November 2024 Reverse Stock Split. However, our periodic and current reports, and all other documents
incorporated by reference into this prospectus that were filed prior to November 18, 2024, do not give effect to the November 2024 Reverse
Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2024, we filed a certificate of amendment
to our restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-8 reverse stock split
of our issued and outstanding shares of common stock, par value $0.0001 per share (the &ldquo;June 2024 Reverse Stock Split&rdquo;), which
became effective on June 20, 2024. All historical share and per share amounts reflected throughout this prospectus have been adjusted
to reflect the June 2024 Reverse Stock Split. However, our periodic and current reports, and all other documents incorporated by reference
into this prospectus that were filed prior to June 20, 2024, do not give effect to the June 2024 Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2023, we filed a certificate of amendment
to our restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split
of our issued and outstanding shares of common stock, par value $0.0001 per share (the &ldquo;2023 Reverse Stock Split&rdquo;), which
became effective on July 24, 2023. All historical share and per share amounts reflected throughout this prospectus have been adjusted
to reflect the 2023 Reverse Stock Split. However, our periodic and current reports, and all other documents incorporated by reference
into this prospectus that were filed prior to July 24, 2023, do not give effect to the 2023 Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information contained
in other parts of this prospectus and in the documents we incorporate by reference. Because it is only a summary, it does not contain
all of the information that you should consider before investing in our securities and it is qualified in its entirety by, and should
be read in conjunction with, the more detailed information appearing elsewhere in this prospectus, any applicable free writing prospectus
and the documents incorporated by reference herein and therein. You should read all such documents carefully, especially the risk factors
and our consolidated financial statements and the related notes included or incorporated by reference herein or therein, before deciding
to buy shares of our common stock. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a medical diagnostics company focused on
improving patient outcomes in critical care settings. We are working on developing rapid, near-patient tests using whole blood on our
Symphony technology platform (&ldquo;Symphony&rdquo;), which consists of an analyzer and single-use protein detection cartridges. We do
not yet have regulatory clearance for Symphony, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration
(the &ldquo;FDA&rdquo;) before Symphony can be marketed as a diagnostic product in the United States. We have completed the pre-clinical
development of the Symphony analyzer. We are redeveloping the manufacturing processes of cartridges through a third-party contractor who
is managing such redevelopment. Such redevelopment is intended to address manufacturing challenges to bring Symphony to a level consistent
with necessary performance and quality requirements. After redevelopment, we plan to have manufacturing of the Symphony cartridges occur
at a Contract Manufacturing Organization (&ldquo;CMO&rdquo;). To achieve our plan, we expect to need to raise at least $20&nbsp;million
of additional capital between the date of this prospectus and the end of the 2027 fiscal year, which we hope to do in various tranches
during this time period. Our current plan, subject to achieving necessary financing, is to begin testing of samples we are collecting
as part of our ongoing SYMON-II clinical trial by the end of 2026, with a goal of being in position to submit a 510(k) regulatory application
to the FDA in 2027, with an objective of achieving FDA clearance thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Symphony platform is a combination of Bluejay&rsquo;s
intellectual property (&ldquo;IP&rdquo;) and exclusively licensed and patented IP on the Symphony technology that we believe, if cleared,
authorized, or approved by the FDA, can provide a solution to a significant market need. The Symphony device candidate is designed to
produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (&ldquo;ICUs&rdquo;) and Emergency
Rooms (&ldquo;ERs&rdquo;), where rapid and reliable results are required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our first product candidate, the Symphony IL-6
test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care
settings. We are currently focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory
biomarker, and is considered a &lsquo;first-responder,&rsquo; for assessment of severity of infection and inflammation across many disease
indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining a
patient&rsquo;s level of severity at triage and we believe that our Symphony IL-6 test, if ultimately successful and approved, could have
the ability to consistently monitor this critical care biomarker with rapid results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we succeed with the foregoing plan, in the
future we hope to develop additional tests for Symphony, including tests for myocardial infarction and congestive heart failure (cardiac
biomarkers hsTNT and NT pro-BNP) as well as other tests using the Symphony platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated under the laws of
Delaware on March 20, 2015. Our headquarters, which is our sole office location, is located in Acton, Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 4, 2021, the Company formed Bluejay Spinco,
LLC, a wholly owned subsidiary of the Company, for purposes of further development of the Company&rsquo;s ALLEREYE diagnostic test. ALLEREYE
is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis. The Company currently is not
actively pursuing development of the ALLEREYE diagnostic test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our Market&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Symphony platform is designed to address a
subset of the global&nbsp;<I>in vitro</I>&nbsp;diagnostics devices (&ldquo;IVDs&rdquo;) market, with a focus on targeting critical care
markets where physicians must quickly determine patient acuity to identify optimal treatment regimens. We are currently focused on our
initial biomarker test, Symphony IL-6 test, in the context of the evaluation of the risk of mortality due to sepsis. We hope in the future
to also explore the potential for adding new biomarker tests to the Symphony platform to also be used in the context of cardio-metabolic
diseases, cancer and other diseases that require rapid tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our Business Model</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently have any revenue-generating
operations. Our goal is to become the first provider of rapid tests for critical care settings, including infectious, inflammatory and
metabolic diseases, by leveraging the strengths of our Symphony platform. We intend to target our sales and marketing of Symphony to the
largest critical care facilities in the United States. Our planned business model, which is contingent on us ultimately obtaining market
clearance and commercializing our Symphony platform, includes the following:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Financing Model</I>. We
intend to offer various financing options for the device itself. As such, our planned business model would not require customers to incur
a significant capital outlay, assuming we are able to successfully offer such financial options.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Recurring Revenue</I>. We
intend to sell single-use diagnostic test cartridges, thereby seeking to create a growing and recurring revenue stream, as adoption and
utilization increase, and as we develop tests for additional indications. We intend that the sale of test cartridges would generate the
majority of our revenue and gross profit.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Expand our Menu of Diagnostic
Products. </I>Our goal would be for the average customer use of the Symphony platform to increase as overall adoption of the product
occurs. If we are able to achieve market clearance in the context of sepsis and then expand our test menu to other diseases and/or conditions,
we hope to be able to increase our annual revenue per customer through the resulting increase in utilization.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The Symphony Platform</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Symphony platform is a proprietary technology
platform that is designed to provide rapid and accurate measurements of key diagnostic biomarkers found in blood in a manner that we believe
is innovative in the market. Symphony is compact and is designed for the potential of it to be deployed in a manner that is more mobile
than current laboratory diagnostic platforms on the market. Symphony incorporates a user-friendly interface where all sample preparation
and reagents are integrated into the disposable Symphony cartridges. Symphony only requires a few drops of blood to provide a measurement
in approximately 20 minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Symphony analyzer is developed and is designed
to orchestrate sample processing (e.g. whole blood, plasma, serum, etc.), biomarker isolation, and immunoassay preparation using non-contact
centrifugal force. All necessary reagents and components are integrated into the Symphony cartridges. Utilizing precision microchannel
technology and high specificity antibodies, liquid samples are processed, and the biomarker is isolated within the Symphony cartridge.
Intermitted centrifugation cycles enable complex fluid movements, allowing sequential reagent additions and independent reaction steps
inside the Symphony cartridge. At the conclusion of the test, the Symphony analyzer measures the fluorescence signature correlating to
a highly sensitive quantitation of the biomarker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To perform a Symphony test, the test operator
adds the sample (e.g. whole blood, plasma, serum, etc.) to the Symphony cartridge. After scanning the patient ID, the Symphony cartridge
is inserted into the Symphony analyzer and the operator initiates the fully automated test. Each analyzer can run up to six cartridges
simultaneously, either with six different patient samples or six different tests, providing quantitative measurements used for improved
patient management and clinical decision-making.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have relied on Toray Industry&rsquo;s
development and manufacturing of the Symphony cartridges. We recently received a final supply of certain chip components from Toray prior
to the expiration of our supply agreement with Toray, which occurred in October 2025. We have encountered several technical challenges
in the performance and quality of the Symphony cartridges, and we are therefore planning to redevelop the manufacturing process for the
cartridges in an attempt to bring Symphony to a level consistent with necessary performance and quality requirements. In particular, the
capture antibody used in the cartridge needs to be replaced. In addition, we are working to correct several reliability and stability
issues with the cartridge product.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently in the process of redeveloping
our cartridge manufacturing processes through Sanyoseiko Co. Ltd. (&ldquo;Sanyoseiko&rdquo;), a third-party contractor who is managing
such redevelopment, and will serve as our CMO for cartridge manufacturing, including for validation testing and commercial manufacturing,
pending regulatory clearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our agreements with Toray, we must use best
efforts to have substantially completed the establishment of our cartridge manufacturing site by October 2026. If Toray were to assert
that the Company has not done so, they could seek to terminate our license agreement with Toray as early as November 2026. If Toray were
to be successful in terminating such license agreement, we would lose access to certain technology required to produce the cartridges
that the Symphony system relies on to function, which would likely result in a material adverse effect on our commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming we are successful in our cartridge manufacturing
process redevelopment, our plan is to begin&nbsp;testing of samples we are collecting as part of our ongoing SYMON-II clinical trial by
the end of 2026, with a goal of being in position to submit a 510(k) regulatory application to the FDA in 2027, and an objective of achieving
FDA clearance thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Manufacturing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to manufacture our analyzers and cartridges
through Sanyoseiko as a contract manufacturing organizations (&ldquo;CMO&rdquo;), and we have entered into master supply and service agreements
with Sanyoseiko governing these matters. Pursuant to statements of work that we will provide to Sanyoseiko under these agreements, Sanyoseiko
will provide end-to-end support for the Symphony platform, including supporting the manufacturing redevelopment process for analyzers
and cartridges (with hardware, software, and design updates), managing raw material sourcing and vendor compliance, and serving as our
contract manufacturing organization for analyzers, cartridges, and related components. In this capacity, Sanyoseiko will oversee fulfillment,
kit assembly, labeling, packaging, shipping, and quality control of manufactured products, while also providing regulatory and quality
management support, and equipment storage and maintenance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sanyoseiko has been selected as our CMO due to
their core competencies in manufacturing and quality systems recognized by the FDA. Sanyoseiko&rsquo;s facilities are located in Japan.
We currently license the technology for the Symphony cartridges from Toray. Our license grants us exclusive global marketing rights, with
the exception of Japan. Bluejay holds the rights to manufacture the analyzers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Government Regulation &ndash; FDA Regulatory
Strategy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The design, development, manufacture, testing
and sale of our products in the U.S. are subject to regulation by numerous governmental authorities, principally the FDA, and corresponding
state and local regulatory agencies. Generally, the products we develop must be cleared by the FDA before they are marketed in the United
States. Before and after approval, authorization, or clearance in the United States, our products are subject to extensive regulation
by the FDA, as well as by other regulatory bodies. FDA regulations govern, among other things, the development, testing, manufacturing,
labeling, safety, storage, recordkeeping, market clearance, authorization or approval, labeling and promotion, import and export, marketing
and sales, and distribution of medical devices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current regulatory strategy is designed to
support commercialization of Symphony in the United States if and when we receive marketing authorization from the FDA. In May 2023, we
submitted a pre-submission application to the FDA presenting study designs to validate Symphony IL-6 for use with hospitalized sepsis
patients. We participated in a pre-submission meeting with the FDA in August 2023, and at the meeting the FDA provided feedback on the
study design, determined that the submission of a 510(k) is the appropriate premarket submission pathway, and requested that certain data
be provided in the 510(k). Based on this feedback, we determined to proceed on this basis, which considers the FDA&rsquo;s feedback.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the second quarter of 2024, we completed a
multicenter SYmphony IL-6 MONitoring Sepsis (&ldquo;SYMON&rdquo;) clinical study investigating the role of interleukin-6 (IL-6) in patients
diagnosed with sepsis and septic shock. This prospective study assessed the performance of IL-6 upon initial presentation to the intensive
care unit (ICU). A primary endpoint of the SYMON-I pilot clinical study (registered clinical trial number NCT06181604) suggested that
IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU may predict patient mortality out to 28 days.
Furthermore, a secondary endpoint of the SYMON-I study suggested that IL-6 levels within 24 hours of sepsis or septic shock diagnosis
and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary endpoints showed that lactate
and Sequential Organ Failure Assessment (SOFA), standard clinical tests used for sepsis and septic shock patients, were not predictors
of patient mortality out to 28 days. We believe that the findings underscore the potential importance of IL-6 as a predictor and provide
new insights into the potential pathways for improving sepsis outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Using the data analysis from the SYMON-I pilot clinical
study, we initiated the SYMON-II pivotal clinical study in the third quarter of 2024. The SYMON II clinical study has three components:
(1) collection, freezing, and biobanking of patient samples, (2) measuring IL-6 concentrations in the biobanked samples near the end of
patient enrollment or after the patient enrollment has completed, and (3) analysis of the IL-6 data with the patient outcomes to see if
the established IL-6 cutoff value has been validated for 28-day all-cause mortality. Patient enrollment started during the fourth quarter
of 2024, and as of the end of the third quarter of 2025, we have enrolled approximately half of our targeted patient population for the
study. Our goal is to use the Symphony IL-6 test to complete the testing in the SYMON-II clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are able to complete the SYMON-II clinical study
and the results are positive, we intend to use the data generated from SYMON-II to support a 510(k) application to the FDA. This application
is currently expected to be based on the following intended use: &ldquo;Symphony IL-6 is intended for use to determine the IL-6 concentration
as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory findings and clinical assessments
for patients diagnosed with sepsis or septic shock in the ICU.&rdquo; We also plan to present the SYMON-I and SYMON-II results at future
national scientific meetings and publish them in peer-reviewed journals, subject to future completion of the Symon-II study and the results
being positive. Subject to achieving needed funding and successfully addressing the technical challenges that our described above, our
plan is to begin&nbsp;testing of samples it is collecting as part of our ongoing SYMON-II clinical trial by the end of 2026, with a goal
of being in position to submit a 510(k) regulatory application to the FDA in 2027, and an objective of achieving FDA clearance thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to engage in and complete the activities
needed for an FDA submission will be contingent upon us addressing these and other challenges, including possessing and/or raising sufficient
capital, remaining a going concern, and producing product capable of supporting our product requirements and meeting analytical validation
and clinical validation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sales and Marketing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until such time as Symphony products may be authorized
by the FDA, our sales and marketing efforts are intended to focus on brand awareness and market education to potential customers, emphasizing
the value of monitoring a critical care patient&rsquo;s IL-6 levels to improve decision making and patient outcomes. If the device is
cleared by the FDA, we intend to target sales to ERs and ICUs at United States hospitals, as well as to long-term acute care facilities.
We hope to establish a market presence by selling Symphony devices and tests both directly and through various distribution channels to
maximize sales volume and market penetration. In addition to our hope to sell Symphony for eventual use in the patient care market, we
are also evaluating sales of Symphony devices for &ldquo;research use only&rdquo; purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We depend on Toray&rsquo;s intellectual property
to develop the Symphony cartridges upon which the Symphony platform relies. We are party to license and supply agreements with Toray,
which provides us with an exclusive global license, excluding Japan, to use Toray&rsquo;s patents and know-how related to the Symphony
detection cartridges for the manufacturing, marketing and sale of the products. In exchange for this license, we committed to make two
payments of $120,000&nbsp;each to Toray, both of which were made in 2021. In addition, following the first sale of the cartridges after
regulatory clearance, we are obligated to make royalty payments to Toray based on the net sales of the cartridges for the period that
any underlying patents exist or ten years after the first sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our agreements with Toray, we must use best
efforts to have substantially completed the establishment of our cartridge manufacturing site by October 2026. If Toray were to assert
that we have not done so, they could seek to terminate the license agreement as early as November 2026. If Toray were to be successful
in terminating the license agreement, we would lose access to certain technology required to produce the cartridges that the Symphony
system relies on to function, which would likely result in a material adverse effect on our commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Intellectual Property, Proprietary Technology</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the fourth quarter of 2024, we submitted a
provisional patent to the U.S. Patent Office. The provisional patent is to establish a priority date to protect certain utilizations of
IL-6 with sepsis patients. We plan to file a Patent Cooperation Treaty (&ldquo;PCT&rdquo;) application in the fourth quarter of 2025 for
the inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently directly hold any granted
patents. We rely on a combination either directly or through the License Agreement with Toray of patent, copyright, trade secret, trademark,
confidentiality agreements, and contractual protection to establish and protect our proprietary rights. Of the patents we rely on, the
protections expire internationally in 2027 and 2028, and in the U.S. in March 2029 and February 2030. As described above, we are currently
working toward a goal of being in position to submit a 510(k) regulatory application to the FDA in 2027 with an objective of achieving
FDA clearance thereafter, which means that even if we meet our timeline, the period of time we will have to commercialize our product
under the protection of these patents is expected to be very narrow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with prior development work performed
by Bluejay, we plan to apply in the future for patent protections related to certain design improvements made to the Symphony technology
platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Competitio</I>n</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are currently no FDA cleared or approved
IL-6 tests on the market. There are IL-6 tests granted FDA Emergency Use Authorization (EUA) for use with only COVID-19 patients, including
the Roche Cobas<SUP>&reg;</SUP>, Siemens ADVIA Centaur<SUP>&reg;</SUP>&nbsp;and Beckman Coulter Access 2<SUP>&reg;</SUP>, which are laboratory
size equipment and require pre-processing of whole blood prior to performing their tests. We believe that Symphony, which is designed
for many liquid sample types including whole blood, provides us with a substantial competitive advantage over our existing competition
that will sustain through commercialization, despite our competitive landscape including existing major life science companies and the
consistent entry of innovative start-ups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Employees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of November 25, 2025, we had 5 full time employees.
We are currently in the process of engaging additional personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also contract with several consultants and
contractors performing accounting, finance, regulatory advisory, investor relations and manufacturing scale-up support. None of our employees
are represented by labor unions or covered by collective bargaining agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>October 2025 Private Placement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2025, the Company entered into a
securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with certain institutional accredited investors, pursuant to which
the Company offered and sold (i) an aggregate of 175,000 PIPE Shares and Pre-Funded Warrants to purchase up to 2,075,000 shares of common
stock, and (ii) Series F Warrants to purchase up to 4,500,000 shares of common stock.&nbsp;The combined price of securities sold in the
private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by
$0.0001) and accompanying Series F Warrants to acquire two shares of common stock.&nbsp;The Pre-Funded Warrants are exercisable for shares
of common stock at an exercise price of $0.0001 per share, are immediately exercisable and expire once exercised in full. The Series F
Warrants are exercisable for shares of common stock at an exercise price of $1.75 per share, are immediately exercisable and expire five
and one-half years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction closed on October 10, 2025. At
closing, the Company received proceeds of approximately $4.0 million after payment to the placement agent of an 8% cash fee and reimbursement
of certain fees and expenses of the placement agent, in each case, pursuant to an engagement letter entered into with the placement agent
on August 29, 2025. In addition, pursuant to such engagement letter, the Company issued to the placement agent (or its designees) Placement
Agent Warrants to purchase up to an aggregate of 180,000 shares of common stock on the same terms as the Series F Warrants, except that
the exercise price per share is 125% of the combined price of the securities sold in the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>April 2025 Private Placement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 7, 2025, the Company entered into inducement
letter agreements (the &ldquo;Inducement Letter Agreements&rdquo;) with certain existing holders of the Company&rsquo;s Class C warrants,
pursuant to which the holders agreed to purchase an aggregate of 1,085,106 shares of our common stock. The Class C warrants were originally
issued to the holders on June 28, 2024 for an exercise price of $98.00 per share and were subsequently reduced to $16.30 per share pursuant
to stockholder approval on August 21, 2024. Pursuant to the Inducement Letter Agreements, the holders agreed to exercise their Series
C warrants at a reduced exercise price of $3.42 per share, and to purchase an equivalent number of new Class E warrants for an additional
$0.125 per share. The Class E warrants have an exercise price of $3.42 per share and expire on April 8, 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction closed on April 8, 2025. The exercise
of the Class C warrants resulted in the Company issuing 1,085,106 shares of common stock at or following closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds to the Company from the exercise
of the Class C warrants and the sale of the new Class E warrants were approximately $3.8 million. The Company incurred total offering
costs of approximately $0.5 million, including a 10% financial advisory fee to Aegis Capital Corp. of approximately $0.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reverse Stock Splits </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2023, we effected a first reverse
stock split of our shares of common stock at a ratio of 1-for-20 (the &ldquo;July 2023 Reverse Stock Split&rdquo;). On June 20, 2024,
we effected a second reverse stock split of our shares of common stock at a ratio of 1-for-8 (the &ldquo;June 2024 Reverse Stock Split&rdquo;).
On November 18, 2024, we effected a third reverse stock split of our shares of common stock at a ratio of 1-for-50 (the &ldquo;November
2024 Reverse Stock Split&rdquo; and together with the July 2023 Reverse Stock Split and the June 2024 Reverse Stock Split, the &ldquo;Reverse
Stock Splits&rdquo;). As such, collectively, the Company&rsquo;s common stock has undergone reverse stock splits that have combined the
shares on a 1-for-8,000 aggregate basis since July 2023. The Reverse Stock Splits became effective on the dates noted above, when the
Company&rsquo;s common stock opened for trading on Nasdaq on a post-split basis under the Company&rsquo;s existing trading symbol, &ldquo;BJDX.&rdquo;
All historical share and per share amounts reflected throughout this prospectus have been adjusted to reflect the Reverse Stock Splits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0; text-align: justify"><B>Risks Associated with Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to a number of risks of
which you should be aware before making an investment decision. These risks are discussed more fully in the &ldquo;Risk Factors&rdquo;
section of this prospectus immediately following this prospectus summary and in Part I, Item 1A &ldquo;Risk Factors&rdquo; of our Annual
Report on Form 10-K for the fiscal year ended December 31, 2024, and in Part II, Item 1A &ldquo;Risk Factors&rdquo; of our Quarterly Reports
on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, each of which are incorporated by reference
into this prospectus. These risks include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have incurred significant
losses since our inception, do not currently generate any operating income, and will continue to incur losses as we work to obtain product
clearance or approval, and thus we may never achieve or maintain profitability.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We will require material additional
funding to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, or at all, and
our lack of cash resources has slowed the timeline of our clinical trial work and could cause us to run out of cash resources in the
near-term.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Since the initial public offering
of our common stock in November 2021, the market price of our common stock has fallen by more than 99.9%, and we expect to need additional
funding amounts substantially greater than the current market capitalization of our common stock, which may result in future dilution
that coincides with further material declines in the trading price of our common stock beyond the substantial declines that have occurred
in recent years.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In connection with any merger,
consolidation or sale of all or substantially all of our assets, holders of our outstanding warrants would be entitled to receive the
Black Scholes value of such warrants, which may reduce the consideration otherwise available for payment to holders of our common stock.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our common stock is currently
listed for quotation on the Nasdaq Capital Market, but we may be unable to meet requirements for continued listing in the future.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our license and supply arrangements
with Toray, which relate to the license of the core technology used in our Symphony Cartridges and the supply of cartridge intermediates
from Toray to Sanyoseiko for Sanyoseiko to manufacture cartridges for Bluejay, are subject to significant risks that may threaten our
viability or otherwise have a material adverse effect on us and our business, assets and its prospects.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We might not be able to discover
the underlying cause of an ongoing performance reproducibility issue with our product, and if the issues are ultimately determined to
be inherent in the design process of the platform, we might have to undertake a significant adjustment to our process and materials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Symphony platform, including
its software and systems, may contain undetected errors, which could limit our ability to provide our products and diminish the attractiveness
of our offerings.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If we or our manufacturers
fail to comply with the regulatory quality system regulations or any applicable equivalent regulations, our proposed operations could
be interrupted, and our operating results would suffer.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If we are found to have violated
laws protecting the confidentiality of patient health information, we could be subject to civil or criminal penalties, which could increase
our liabilities and harm our reputation or our business.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Significant raw material shortages,
supplier capacity constraints, supplier disruptions, and sourcing issues may adversely impact or limit our products sales and or impact
our product margins.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to solve ongoing
issues with stability, and reliability of the Symphony Cartridge product may adversely impact our ability to complete clinical trial
work and commercialize Symphony.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The regulatory clearance process
which we may be required to navigate may be expensive, time-consuming, and uncertain and may prevent us from obtaining clearance for
our planned products.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Clinical data obtained in the
future may not meet the required objectives, which could delay, limit or prevent any regulatory clearance or approval.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We may be unable to complete
required clinical evaluations, or we may experience significant delays in completing such clinical evaluations, which could prevent or
significantly delay our targeted product launch timeframe and impair our viability and business plan.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We and our suppliers may not
meet regulatory quality standards applicable to our manufacturing processes, which could have an adverse effect on our business, financial
condition, and results of operations.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We depend on intellectual property
licensed from Toray, and any dispute over the license would significantly harm our business.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We will depend primarily on
Toray to file, prosecute, maintain, defend and enforce intellectual property that we license from it and that is material to our business.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We and Toray may be unable to protect or enforce the intellectual property rights licensed to us, which could impair our competitive position.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We and/or Toray may be subject to claims alleging the violation of the intellectual property rights of others.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are currently only pursuing one aspect of analytical validation, one of three series of validation tests required for FDA clearance, and we cannot be certain how long the remaining tests will take us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The FDA could request additional data or testing after our submission for application, requiring additional costs and delaying clearance or approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We face intense competition in the diagnostic testing market, particularly in the IL-6 space, and as a result we may be unable to effectively compete in our industry.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sales of substantial amounts of our securities in the public market could depress the market price of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have material adverse effect on our business and stock price. Our President and Chief Executive Officer, in addition to serving as principal executive officer, currently serves as our principal financial and accounting officer, and we have no employees devoted on a full-time basis to our finance, accounting, legal or compliance functions, which may substantially increase the likelihood that we will fail to successfully maintain effective internal controls over financial reporting, or effective disclosure controls and procedures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0"><B>Implications of Being an Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an emerging growth company as defined in
the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). We may remain an &ldquo;emerging growth company&rdquo; until
as late as December 31, 2027 (the fiscal year-end following the fifth anniversary of the completion of our initial public offering, though
we may cease to be an &ldquo;emerging growth company&rdquo; earlier under certain circumstances, including (1) if the market value of
our common stock that is held by nonaffiliates exceeds $700 million as of any June 30, in which case we would cease to be an &ldquo;emerging
growth company&rdquo; as of the following December 31, or (2) if our gross revenue exceeds $1.235 billion in any fiscal year. &ldquo;Emerging
growth companies&rdquo; may take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of
2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments
not previously approved. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price
may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Section 102 of the JOBS Act also
provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section 7(a)(2)(B)
of the Securities Act, for complying with new or revised accounting standards. An &ldquo;emerging growth company&rdquo; can therefore
delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated under the laws of the State
of Delaware on March 20, 2015. Our principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720 and
our telephone number is (844) 327-7078. Our website address is www.bluejaydx.com. We do not incorporate the information on, or accessible
through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>The Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%">Shares of common stock offered by the<BR>
 Selling Stockholders: &nbsp;</TD>
    <TD STYLE="width: 62%"><FONT STYLE="font-size: 10pt">6,930,000 shares of common stock</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Terms of this offering:</FONT></TD>
    <TD STYLE="text-align: justify">The Selling Stockholders may sell, transfer or otherwise dispose of any or all of the Shares offered by this prospectus from time to time as described under the caption &ldquo;Plan of Distribution&rdquo; in this prospectus &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Use of proceeds:</FONT></TD>
    <TD STYLE="text-align: justify">All proceeds from the sale of shares of common stock offered hereby will be for the account of the Selling Stockholders. We will not receive any proceeds from the sale of common stock offered hereunder, although we will receive the net proceeds of any Warrants exercised for cash. See the caption &ldquo;Use of Proceeds&rdquo; in this prospectus. &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk factors:</FONT></TD>
    <TD STYLE="text-align: justify">Investing in our common stock involves a high degree of risk and purchasers of our common stock may lose their entire investment. See the information under the caption &ldquo;Risk Factors&rdquo; on page 10 of this prospectus and the other information included elsewhere in this prospectus and incorporated by reference herein for a discussion of factors you should consider before deciding to invest in our securities. &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Nasdaq Capital Market symbol:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">BJDX</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When we refer to the Selling Stockholders in this
prospectus, we are referring to the Selling Stockholders identified in this prospectus and, as applicable, their permitted transferees,
or other successors-in-interest that may be identified in a supplement to this prospectus or, if required, a post-effective amendment
to the registration statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our common stock involves a high
degree of risk. You should carefully consider and evaluate all of the information contained in this prospectus and in the documents incorporated
by reference in this prospectus before you decide to purchase our common stock. In particular, you should carefully consider and evaluate
the risks and uncertainties described in &ldquo;Part I &ndash; Item 1A. Risk Factors&rdquo; of our most recent Annual Report on Form
10-K for the fiscal year ended December 31, 2024 and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025,
June 30, 2025, and September 30, 2025, which are each incorporated by reference into this prospectus, as updated by the additional risks
and uncertainties set forth or incorporated by reference herein. Additional risks and uncertainties that we are unaware of or that we
believe are not material at this time could also materially adversely affect our business, financial condition, or results of operations.
Any of these risks and uncertainties could materially and adversely affect our business, results of operations, and financial condition,
which in turn could materially and adversely affect the trading price or value of our common stock. As a result, you could lose all or
part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This prospectus also contains forward-looking
statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking
statements as a result of certain factors, including the risks faced by us described below and elsewhere in this prospectus. See &ldquo;Special
Note Regarding Forward-Looking Statements&rdquo; for information relating to these forward-looking statements. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the documents incorporated
herein by reference contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can
identify these statements by forward-looking words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue,&rdquo; and the negative of these terms and
other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions
about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business.
These statements are only predictions based on our current expectations and projections about future events. There are important factors
that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity,
performance or achievements expressed or implied by the forward-looking statements. We have included important factors in the cautionary
statements included in this prospectus, particularly under &ldquo;Risk Factors&rdquo; on page 10 of this prospectus and the documents
incorporated herein that we believe could cause actual results or events to differ materially from the forward-looking statements that
we make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we believe we have identified material risks
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and our Quarterly Reports on Form 10-Q for the fiscal quarters
ended March 31, 2025, June 30, 2025, and September 30, 2025, which are each incorporated by reference in this prospectus, together with
the information included in this prospectus and the documents incorporated by reference herein, and in any free writing prospectus that
we have authorized for use in connection with this offering, these risks and uncertainties are not exhaustive. Other sections of this
prospectus and the documents incorporated herein by reference may describe additional factors that could adversely impact our business
and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge
from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we believe the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.
Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. You should read this prospectus and any free writing
prospectus and the documents that we have incorporated by reference to this prospectus and filed as exhibits to this prospectus completely
and with the understanding that our actual future results may be materially different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We caution you not to place undue reliance on
the forward-looking statements, which speak only as of the date of this prospectus in the case of forward-looking statements contained
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not rely upon forward-looking statements
as predictions of future events. Our actual results and financial condition may differ materially from those indicated in the forward-looking
statements. We qualify all of our forward-looking statements by these cautionary statements. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Therefore, you should not rely on any of the forward-looking statements. In addition, with respect to all of our forward-looking statements,
we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of
1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as required by law, we undertake no obligation
to update or revise any forward-looking statements to reflect new information or future events or developments. You should not assume
that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before
deciding to purchase our securities, you should carefully consider the risk factors discussed and incorporated by reference in this prospectus
and the documents incorporated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds from any disposition of the Shares
will be received by the Selling Stockholders. We will not receive any of the proceeds from any such Shares offered by this prospectus.
We will, however, receive the net proceeds of any Warrants exercised for cash. We intend to use the net proceeds from the exercise of
the Warrants to fund matters related to obtaining FDA approval (including clinical studies related thereto), as well as for other research
and development activities, and for general working capital needs. We have agreed to pay all costs, expenses, and fees relating to the
registration of the Shares covered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>SELLING STOCKHOLDERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shares being offered by the selling shareholders
are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the Warrants.
For additional information regarding the issuances of the Shares and the Warrants, see &ldquo;Prospectus Summary&#8239;- October 2025
Private Placement&rdquo; above. We are registering the Shares in order to permit the selling shareholders to offer the Shares for resale
from time to time. The selling shareholders have not had any material relationship with us within the past three years, except for the
ownership of our common stock and warrants to purchase our common stock and related agreements entered into in connection with the acquisition
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below lists the selling shareholders and
other information regarding the beneficial ownership of shares of our common stock by each of the selling shareholders. The second column
lists the number of shares of our common stock beneficially owned by each selling shareholder, based on its ownership of shares of our
common stock and warrants to purchase our common stock, as of November 25, 2025, assuming exercise of the warrants held by the selling
shareholders on that date, without regard to any limitations on exercises. The percentage of beneficial ownership after this offering
is based on 1,814,133 shares outstanding on November 25, 2025 (together with any newly-issued shares sold by such Selling Stockholder
in the offering).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third column lists the shares of common stock
being offered by this prospectus by the selling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the terms of a registration
rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i) the number of shares of
common stock issued to the selling shareholders in the &ldquo;Prospectus Summary&#8239;- October 2025 Private Placement&rdquo; described
above and (ii) the maximum number of shares of common stock issuable upon exercise of the related warrants, determined as if the outstanding
warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with
the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided
in the registration right agreement, without regard to any limitations on the exercise of the warrants. The fourth column assumes the
sale of all of the shares offered by the selling shareholders pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Warrants and other warrants
held by selling shareholders, a selling shareholder may not exercise any such warrants to the extent such exercise would cause such selling
shareholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would
exceed 4.99% or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination
shares of our common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second and
fourth columns do not reflect this limitation. The selling shareholders may sell all, some or none of their shares in this offering. See
&quot;Plan of Distribution.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Beneficial Ownership<BR> Before This Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Beneficial Ownership After This Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Selling Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares<BR> Beneficially<BR> Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> Shares Being Offered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares<BR> Beneficially<BR> Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage<BR> of<BR> Outstanding<BR> Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"><FONT STYLE="font-size: 10pt">Armistice Capital, LLC <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,650,478</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,625,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">25,478</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Augustus Trading LLC<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">David Dinkin<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Intracoastal Capital LLC<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,125,069</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Wilson Drive Holdings LLC<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Less than 1%</FONT></TD>
</TR></TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares of common stock being offered hereby include (i) 1,875,000 shares of common stock issuable upon the exercise of Pre-Funded Warrants subject to a 9.99% ownership cap, (ii) 3,750,000 shares of common stock issuable upon the exercise of Series F Warrants subject to a 4.99% ownership cap, and (iii) additional shares of common stock issuable upon the exercise of other Company warrants. The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &ldquo;Master Fund&rdquo;), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&ldquo;Armistice Capital&rdquo;), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022. &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 78,975 shares issuable upon exercise of Placement Agent Warrants. Orsium Capital LLC, the authorized agent to Augustus Trading LLC, has discretionary authority to vote and dispose of the securities held by Augustus Trading LLC and may be deemed to be the beneficial owner of these securities. Olivier Morali, in his capacity as managing member of Orsium Capital LLC, may also be deemed to have investment discretion and voting power over the shares held by Augustus Trading LLC. Orsium Capital LLC and Mr. Morali each disclaims any beneficial ownership of these securities. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Stockholder is affiliated with Rodman, a registered broker-dealer with a registered address of Rodman &amp; Renshaw LLC, 600 Lexington Avenue, 32nd Floor, New York, NY 10022. Rodman acted as our placement agent in the Warrant Inducement and the 2025 Offering. The Selling Stockholder has sole voting and dispositive power over the securities held, acquired the securities in the ordinary course of business and, at the time the securities were acquired, the Selling Stockholder had no agreement or understanding, directly or indirectly, with any person to distribute such securities. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares of common stock being offered hereby include (i) 200,000 shares of common stock issuable upon the exercise of Pre-Funded Warrants subject to a 9.99% ownership cap and (ii) 750,000 shares of common stock issuable upon the exercise of Series F Warrants subject to a 4.99% ownership cap. The securities are directly held by Intracoastal Capital LLC, a Delaware limited liability company (&ldquo;Intracoastal&rdquo;) and may be deemed to be beneficially owned by Mitchell P. Kopin (&ldquo;Mr. Kopin&rdquo;) and Daniel B. Asher (&ldquo;Mr. Asher&rdquo;), each of whom are managers of Intracoastal Capital LLC (&ldquo;Intracoastal&rdquo;), have shared voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)) of the securities reported herein that are held by Intracoastal. Intracoastal Capital LLC&rsquo;s address is 245 Palm Trail, Delray Beach, FL 33483. &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 30,375 shares issuable upon exercise of Placement Agent Warrants. Craig Schwabe is the managing member of Wilson Drive Holdings LLC and has the power to vote and dispose of the securities held. Mr. Schwabe is affiliated with Rodman &amp; Renshaw LLC, a registered broker-dealer with a registered address of Rodman &amp; Renshaw LLC, 600 Lexington Avenue, 32nd Floor, New York, NY 10022. The securities were acquired in the ordinary course of business and, at the time the securities were acquired, the Selling Stockholder had no agreement or understanding, directly or indirectly, with any person to distribute such securities. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Each Selling Stockholder and
any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their Shares covered hereby on
the principal Trading Market or any other stock exchange, market or trading facility on which the Company&rsquo;s common stock is traded
or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following
methods when selling Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which
the broker-dealer solicits purchasers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt to sell
the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an exchange distribution in accordance with the rules of
the applicable exchange;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">privately negotiated transactions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">settlement of short sales;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">in transactions through broker-dealers that agree with the
Selling Stockholders to sell a specified number of such Shares at a stipulated price per security;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a combination of any such methods of sale; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any other method permitted pursuant to applicable law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Selling Stockholders may
also sell Shares under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Broker-dealers engaged by
the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in
compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In connection with the sale
of the Shares or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling
Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Each Selling Stockholder has
informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to
distribute the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company is required to
pay certain fees and expenses incurred by the Company incident to the registration of the Shares. The Company has agreed to indemnify
the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We agreed to keep this prospectus
effective until the earlier of (i) the date on which the Shares may be resold by the Selling Stockholders without registration and without
regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance
with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the Shares
have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities
will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in
certain states, the Shares covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state
or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Under applicable rules and regulations under the
Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities
with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution.
In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder,
including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other
person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy
of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_009"></A>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the shares of common stock offered
hereby is being passed upon for us by Hogan Lovells US LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_010"></A>EXPERTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wolf &amp; Company P.C., independent registered
public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K, for the year ended
December 31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial
doubt about our ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated
by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in
reliance on Wolf &amp; Company P.C.&rsquo;s report, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_011"></A><B>INCORPORATION BY REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information into this prospectus, which means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-41031. The documents
incorporated by reference into this prospectus contain important information that you should read about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following documents are incorporated by reference into this document:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1704287/000121390025026275/ea0234502-10k_bluejay.htm"><FONT STYLE="font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-size: 10pt">for the fiscal year ended December 31, 2024, filed on March 31, 2025, as amended by </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025036783/ea0239880-10ka1_bluejay.htm"><FONT STYLE="font-size: 10pt">Amendment No. 1</FONT></A> <FONT STYLE="font-size: 10pt">thereto, filed on April 29, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Quarterly Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025042633/ea0241317-10q_bluejay.htm"><FONT STYLE="font-size: 10pt">Form 10-Q</FONT></A> <FONT STYLE="font-size: 10pt">for the fiscal quarter ended March 31, 2025, filed on May 13, 2025,  our Quarterly Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025073064/ea0251376-10q_bluejay.htm"><FONT STYLE="font-size: 10pt">Form 10-Q</FONT></A> <FONT STYLE="font-size: 10pt">for the fiscal quarter ended June 30, 2025, filed on August 7, 2025, and our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1704287/000121390025107599/ea0263951-10q_bluejay.htm">Form 10-Q</A> for the fiscal quarter ended
September 30, 2025, filed on November 7, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">those portions of our </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025044931/ea0240857-02.htm"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></A> <FONT STYLE="font-size: 10pt">on Schedule 14A filed on May 16, 2025 that are deemed &ldquo;filed&rdquo; with the SEC;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that relate to such items) filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025030312/ea0237671-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">April 9, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025048343/ea0243732-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">May 28, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025050913/ea0244646-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">June 4, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025055724/ea0246255-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">June 20, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025068296/ea0250447-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">July 28, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390025077600/ea0253600-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">August 15, 2025</FONT></A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001704287/000121390025097564/ea0260646-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">October 9, 2025</FONT></A> <FONT STYLE="font-size: 10pt">and </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001704287/000121390025098281/ea0260965-8k_bluejay.htm"><FONT STYLE="font-size: 10pt">October 14, 2025</FONT></A><FONT STYLE="font-size: 10pt">; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The description of our common stock, par value $0.0001 per share contained in its Registration Statement on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1704287/000121390021057034/ea150059-8a12b_bluejay.htm"><FONT STYLE="font-size: 10pt">Form 8-A</FONT></A><FONT STYLE="font-size: 10pt">, dated and filed with the SEC on November 5, 2021, as amended by the description of our common stock contained in </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1704287/000121390025026275/ea023450201ex4-10_bluejay.htm"><FONT STYLE="font-size: 10pt">Exhibit 4.10</FONT></A> <FONT STYLE="font-size: 10pt">to our Annual Report on Form 10-K for the year ended December 31, 2024, including all amendments and reports updating that description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference into this prospectus
all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are
related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the
date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement
and all documents that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date
of this prospectus but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form
10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any statement contained herein or in a document
incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of
the document to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be
incorporated by reference into this document modifies or supersedes the statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide without charge to each person,
including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that
are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such documents unless
such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates. You should direct oral
or written requests by one of the following methods. Attention: Investor Relations, Bluejay Diagnostics, Inc., 360 Massachusetts Avenue,
Suite 203, Acton, MA, 01720, (844) 327-7078. You may also access these documents, free of charge on the SEC&rsquo;s website at www.sec.gov
or on the &ldquo;Investors&rdquo; page of our website at www.bluejaydx.com. The information found on our website, or that may be accessed
by links on our website, is not part of this prospectus. We have included our website address solely as an inactive textual reference.
Investors should not rely on any such information in deciding whether to purchase our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We filed with the SEC a registration statement
under the Securities Act for the securities offered by this prospectus. This prospectus does not contain all of the information in the
registration statement and the exhibits and schedule that were filed with the registration statement. For further information with respect
to us and our securities, we refer you to the registration statement and the exhibits and schedule that were filed with the registration
statement. Statements contained in this prospectus about the contents of any contract or any other document that is filed as an exhibit
to the registration statement are not necessarily complete, and we refer you to the full text of the contract or other document filed
as an exhibit to the registration statement. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy
and information statements, and other information regarding registrants that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file periodic reports and current reports under
the Exchange Act, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other information
with the Securities and Exchange Commission. These periodic reports and other information are available for inspection and copying at
the SEC regional offices, public reference facilities and on the website of the SEC referred to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We make available free of charge on or through
our internet website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those
reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the SEC. The information found on our website, www.bluejaydx.com, other
than as specifically incorporated by reference in this prospectus, is not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ .D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^B3_@K_\
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MFVM>9..UK-ZH_8 =!GK@9K\2_P#@O[_RC_OO^RS_  Q_GKE?MH.@^@K\2_\
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MG[#OB;5_&.E:Q;FPU*S\2ZS\%IGUX:PN<)(D\LN]2"=F1D858_Q'_P"#:_\
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M^!W@C6]*\8^$=/\ &7AWXF>-M7US4-)US.N)H.OZ&F@: _A3;K_A?RXW*_\
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M^;6]>\+@!R_C'P7P6# F@?\ 7Z_EKZ:[']Q=?RV_\'*__'C^QQ_U_?'?_P!
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M_99^*:>)KC08$L?#MYXH_P"%8ZW_ &PVE#7F9UT"77/GB,S&<VY0S;97=%_
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M_9HU'X-_%5O#S>!-8UTX/R>%@/ _B:3&24T)AD<$>P_\%._$7B+]OK_@J3X
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MSCUXI<#T'Y"BBHWW/222BDDDK+1));+HE;\# ;2]*)&JG2]/-_@?Z0;9-_)
MY/4GW)SZFN@P!T&*** 48K:,5Z12_)(*0JIZJ#]0*** :3T:379I-?<TU^ !
M5'10,]< "@JIQD XZ9 ./I111=]W][#ECMRQMVY5;OM:V^NV^H8'H/RHP!T
M'X4447?=A9=E]R_R%P/3_)ZTFU3G*@YZ\#GZT447"R>Z3]4G^:#:N,;1CTP,
M?ETHVKC&T8],#%%%%WW?WL++LMK;+;MMMY;>08'H/R%&!Z#UZ=_6BB@8A53U
M53]0#_2G8'H***!62NTDF]VDDWZNUW\VPHHHH&%%%% !1110 4444 %%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
